Jaguar Health, Inc.
Jaguar Health, Inc. (JAGX): 4 pipeline candidates · 1 upcoming catalyst · ~5 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
4.9 months
N/A
Lead: Approved
4 candidates
1 upcoming, next in ~1961d
N/A
A transparent, data-derived signal for Jaguar Health, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.8M
Cash
$10.1M
Quarterly Burn
$8.0M
Runway
4.9 mo
Revenue
$20.3M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| canalevia-ca1 | Approved |
| crofelemer powder for | Phase 3 |
| mytesi | Approved |
| np-300 | Preclinical |
Upcoming Catalysts (1)
Frequently asked questions
How many drug candidates are in Jaguar Health, Inc.'s pipeline?
Jaguar Health, Inc. (JAGX) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Jaguar Health, Inc.'s lead drug candidate?
Jaguar Health, Inc.'s most advanced tracked candidate is canalevia-ca1 (Approved) for chemotherapy-induced diarrhea (CID) in dogs.
What is Jaguar Health, Inc.'s next catalyst?
Jaguar Health, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: MYTESI" — expected October 31, 2031.
What is Jaguar Health, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Jaguar Health, Inc. has approximately 4.9 months of cash runway.
What is Jaguar Health, Inc.'s market capitalization?
Jaguar Health, Inc.'s market capitalization is approximately $1.8M.
Get the full picture on Jaguar Health, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.